SCHEMBL525153

SCHEMBL525153

O=CCc1ccc2cc(Br)ccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.46
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
TLR2 O60603 1/20 0.42
ERN1 O75460 2/20 0.41
MAOB P27338 3/20 0.37
MAOA P21397 2/20 0.37
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NCEH1 Q6PIU2 1/20 0.36
ACHE P22303 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
BACE1 P56817 1/20 0.34
PIM1 P11309 1/20 0.34
RAB9A P51151 1/20 0.34
RIOK2 Q9BVS4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27963834 0.82 CYP2A6 (0.42) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL2425555 0.82 XDH (0.47) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL720558 0.78 CYP1A2 (0.56) CYP2A6KMT2ARAB9A
SCHEMBL29955760 0.78 CYP1A2 (0.56) CYP2A6KMT2ARAB9A
SCHEMBL15352007 0.78 CYP2A6 (0.50) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL27774313 0.77 CYP2A6 (0.41) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL20103 0.77 CYP2A6 (0.44) CYP2A6MEN1KMT2AMAOBMAOA
SCHEMBL11739548 0.77 CYP1A2 (0.59) CYP2A6MEN1ALDH1A1MAPTKMT2A
SCHEMBL29058801 0.77 CYP1A2 (0.48) CYP2A6ALDH1A1KMT2ARAB9A
SCHEMBL11634757 0.77 CYP1A2 (0.48) CYP2A6ALDH1A1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2797913-A1 QUINAZOLINONE DERIVATIVES AS HCV INHIBITORS Janssen R&D Ireland (IE) 2014-11-05 EP disclosed
WO-2013098320-A1 QUINAZOLINONE DERIVATIVES AS HCV INHIBITORS JANSSEN R&D IRELAND (IE) 2013-07-04 WO disclosed
EP-2598498-A1 HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS Janssen R&D Ireland (IE) 2013-06-05 EP disclosed
WO-2012123298-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 WO disclosed
EP-2499115-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-09-19 EP disclosed
EP-2499127-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-09-19 EP disclosed
EP-2496572-A1 BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES Janssen R&D Ireland (IE) 2012-09-12 EP disclosed
WO-2012013643-A1 HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS TIBOTEC PHARMACEUTICALS (IE) 2012-02-02 WO disclosed
WO-2011091446-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2011-07-28 WO disclosed
WO-2011059887-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 WO disclosed
WO-2011059850-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 WO disclosed
WO-2011054834-A1 BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES TIBOTEC PHARMACEUTICALS (IE) 2011-05-12 WO disclosed
WO-2010127208-A1 INHIBITORS OF ACETYL-COA CARBOXYLASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-11-04 WO disclosed
EP-2024272-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Renovis, Inc. (US) 2009-02-18 EP disclosed
WO-2007133637-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2007-11-22 WO disclosed
US-4447452-A ANTIDIABETIC AGENT AYERST, MCKENNA & HARRISON INC. (CA) 1984-05-08 US disclosed